Test your knowledge on managing a patient newly diagnosed with MM and ineligible for stem-cell transplant

The induction regimen of daratumumab, lenalidomide, and dexamethasone is appropriate for induction therapy for a newly diagnosed transplant-ineligible patient given its ability to achieve which of the following?
Produce high levels of minimal residual disease
Prolong overall survival
Have a PFS of 34.4 months
Reduce the risk of hypersensitivity reactions
Bone disease in multiple myeloma is a result of which of the following?
Induced osteoblast function
Plasma cells reducing osteoclast function
Osteoclastic bone destruction
Bone-modifying agents
The results of the EMNO11/HOVON114 trial demonstrated which of the following, regarding KPd?
It is an effective regimen in front-line therapy for transplant-ineligible patients
It is an effective regimen for patients who are refractory to pomalidomide
It is an effective regimen with no VTE risk
It is an effective regimen for patients who are refractory to lenalidomide
0
{"name":"Test your knowledge on managing a patient newly diagnosed with MM and ineligible for stem-cell transplant", "url":"https://www.quiz-maker.com/QGN8YXV8S","txt":"The induction regimen of daratumumab, lenalidomide, and dexamethasone is appropriate for induction therapy for a newly diagnosed transplant-ineligible patient given its ability to achieve which of the following?, Bone disease in multiple myeloma is a result of which of the following?, The results of the EMNO11\/HOVON114 trial demonstrated which of the following, regarding KPd?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}